Molecular testing of lymphoproliferative disorders

Current status and perspectives

The Hematopathology Study Group of the Korean Society of Pathologists, The Molecular Pathology Study Group of Korean Society of Pathologists

Research output: Contribution to journalReview articleResearchpeer-review

2 Citations (Scopus)

Abstract

Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cellof- origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.

Original languageEnglish
Pages (from-to)224-241
Number of pages18
JournalJournal of Pathology and Translational Medicine
Volume51
Issue number3
DOIs
StatePublished - 1 May 2017

Fingerprint

Lymphoproliferative Disorders
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Cytogenetics
Molecular Biology
Guidelines
T-Lymphocytes
Neoplasms
Therapeutics

Keywords

  • Clonality test
  • Fluorescence
  • Gene translocation
  • In situ hybridization
  • Lymphoproliferative disorders
  • Malignant lymphoma
  • Molecular
  • Molecular diagnostics
  • Next-generation sequencing
  • Pathology

Cite this

The Hematopathology Study Group of the Korean Society of Pathologists, & The Molecular Pathology Study Group of Korean Society of Pathologists (2017). Molecular testing of lymphoproliferative disorders: Current status and perspectives. Journal of Pathology and Translational Medicine, 51(3), 224-241. https://doi.org/10.4132/jptm.2017.04.09
The Hematopathology Study Group of the Korean Society of Pathologists ; The Molecular Pathology Study Group of Korean Society of Pathologists. / Molecular testing of lymphoproliferative disorders : Current status and perspectives. In: Journal of Pathology and Translational Medicine. 2017 ; Vol. 51, No. 3. pp. 224-241.
@article{8ff63418e72f46afa5bb415c0f38c9ef,
title = "Molecular testing of lymphoproliferative disorders: Current status and perspectives",
abstract = "Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cellof- origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.",
keywords = "Clonality test, Fluorescence, Gene translocation, In situ hybridization, Lymphoproliferative disorders, Malignant lymphoma, Molecular, Molecular diagnostics, Next-generation sequencing, Pathology",
author = "{The Hematopathology Study Group of the Korean Society of Pathologists} and {The Molecular Pathology Study Group of Korean Society of Pathologists} and Jeon, {Yoon Kyung} and Yoon, {Sun Och} and Paik, {Jin Ho} and Kim, {Young A} and Shin, {Bong Kyung} and Kim, {Hyun Jung} and Cha, {Hee Jeong} and Kim, {Ji Eun} and Jooryung Huh and Ko, {Young Hyeh}",
year = "2017",
month = "5",
day = "1",
doi = "10.4132/jptm.2017.04.09",
language = "English",
volume = "51",
pages = "224--241",
journal = "Journal of Pathology and Translational Medicine",
issn = "2383-7837",
publisher = "Korean Society of Pathologists",
number = "3",

}

The Hematopathology Study Group of the Korean Society of Pathologists & The Molecular Pathology Study Group of Korean Society of Pathologists 2017, 'Molecular testing of lymphoproliferative disorders: Current status and perspectives', Journal of Pathology and Translational Medicine, vol. 51, no. 3, pp. 224-241. https://doi.org/10.4132/jptm.2017.04.09

Molecular testing of lymphoproliferative disorders : Current status and perspectives. / The Hematopathology Study Group of the Korean Society of Pathologists; The Molecular Pathology Study Group of Korean Society of Pathologists.

In: Journal of Pathology and Translational Medicine, Vol. 51, No. 3, 01.05.2017, p. 224-241.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Molecular testing of lymphoproliferative disorders

T2 - Current status and perspectives

AU - The Hematopathology Study Group of the Korean Society of Pathologists

AU - The Molecular Pathology Study Group of Korean Society of Pathologists

AU - Jeon, Yoon Kyung

AU - Yoon, Sun Och

AU - Paik, Jin Ho

AU - Kim, Young A

AU - Shin, Bong Kyung

AU - Kim, Hyun Jung

AU - Cha, Hee Jeong

AU - Kim, Ji Eun

AU - Huh, Jooryung

AU - Ko, Young Hyeh

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cellof- origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.

AB - Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cellof- origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.

KW - Clonality test

KW - Fluorescence

KW - Gene translocation

KW - In situ hybridization

KW - Lymphoproliferative disorders

KW - Malignant lymphoma

KW - Molecular

KW - Molecular diagnostics

KW - Next-generation sequencing

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=85019860681&partnerID=8YFLogxK

U2 - 10.4132/jptm.2017.04.09

DO - 10.4132/jptm.2017.04.09

M3 - Review article

VL - 51

SP - 224

EP - 241

JO - Journal of Pathology and Translational Medicine

JF - Journal of Pathology and Translational Medicine

SN - 2383-7837

IS - 3

ER -

The Hematopathology Study Group of the Korean Society of Pathologists, The Molecular Pathology Study Group of Korean Society of Pathologists. Molecular testing of lymphoproliferative disorders: Current status and perspectives. Journal of Pathology and Translational Medicine. 2017 May 1;51(3):224-241. https://doi.org/10.4132/jptm.2017.04.09